Lilly Foundation gift to Indiana University Cancer Center

May 16, 2006

INDIANAPOLIS -- Indiana University Cancer Center's future as a premiere clinical and research institution has received a boost with a $7.5 million gift from the Eli Lilly and Company Foundation.

The gift is the largest one-time donation from the Lilly Foundation to an institution or cause. The funds will be used to recruit nationally recognized cancer scientists to strengthen the research initiatives and progressive care available in Indiana.

"The Eli Lilly and Company Foundation and Lilly employees are committed to improving the quality of cancer care and the quality of life for cancer patients," said Sidney Taurel, Eli Lilly and Company chairman and chief executive office. "This gift of $7.5 million represents that commitment and acknowledges our appreciation of the vision shared by the caregivers and researchers at IU Cancer Center and Lilly scientists."

Taurel added that given the other investments being made by Indiana University School of Medicine and Clarian Health that benefit the IU Cancer Center, including the construction of a new cancer treatment facility and a new research building, Lilly believes that this is an ideal time to support the growth of the program as it increases its national reputation as a leader in cancer research and patient care.

"The Eli Lilly and Company Foundation's support of the IU Cancer Center will elevate the standards of cancer care throughout Indiana and throughout the country," said Center Director Stephen D. Williams, M.D., the HH Gregg Professor of Oncology and professor of medicine at the IU School of Medicine. "Our research and clinical programs are expanding and so are the partnerships necessary for us to achieve our goals."

The IU Cancer Center is the only National Cancer Institute-designated center in the state where research and patient care come together. The NCI distinction is awarded to an elite group of research centers whose focus is the rapid translation of research discoveries into treatments for people with cancer.

IU Cancer Center physicians and scientists are well known for bringing cutting-edge research to clinic care; an early example of this is the cure for testicular cancer developed in 1974 by Lawrence Einhorn, M.D., Distinguished Professor and the Lance Armstrong Foundation Professor in Oncology. Since that time, IU Cancer Center physicians and scientists have played a national role in the development of new treatments for several types of cancer, including breast, lung, and blood-borne cancers such as leukemia.

Developing new cancer treatments is a complex and multi-dimensional process requiring collaborative efforts among researchers in various fields. The Eli Lilly and Company Foundation gift will allow the IU Cancer Center to attract top-tier scientists and physicians and give them the resources they need for this work.

Creating and improving patient care based on scientific discoveries and solutions developed in the lab historically has been referred to as a "bench to bedside" process and more recently dubbed translational science.

"The Eli Lilly and Company Foundation gift will help the IU Cancer Center meet its goal to take a national leadership role in emerging areas of cancer research," said D. Craig Brater, M.D., dean of the IU School of Medicine and IU vice president with life science responsibilities. "Most importantly, patients will benefit from the collaborations of our scientists and physicians, which are enhanced by this gift."

The IU Cancer Center, with 168 physician and researcher members, is expanding its research and clinical care spaces. Last fall, ground was broken for a $150 million structure that will be connected to Indiana University Hospital. The facility expansion, a collaboration between the IU School of Medicine and Clarian Health, will make the most advanced treatment technologies and modern, comfortable resources available in a 405,216- square-foot building scheduled to open in 2008.

Also under construction is a 254,000-square-foot building, Research III, which will be the fourth and the largest research facility built since 2000 by the medical school. When finished in 2008, it will house researchers focusing on the biology and chemistry of cancer, as well as other health issues.
The Eli Lilly and Company Foundation was established in 1968 to carry out philanthropic interests. The foundation is funded from the company's profits and is the major source of the company's support for not-for-profit and charitable organizations around the world.

For more information on the Eli Lilly and Company Foundation, see For additional information on the IU Cancer Center, see

Indiana University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to